CATALAYER NEWS
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-10-24
Full article text is available in the Catalayer news terminal.
MORE FROM FINANCIAL TIMES
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engage
2026-10-25
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant
2026-10-25
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta
2026-10-25
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ mo
2026-10-25
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progressi
2026-10-25
RELATED ON CATALAYER
RELATED MARKETS
Prediction Markets